{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011964","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2023-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.264811+00:00","generated_at":"2026-06-13T06:29:03.361373+00:00","sec_items":["1.01","3.02","5.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kiromic BioPharma exchanges $6M of 25% Senior Notes for Series C Preferred Stock","bullets":["Exchanged $6M aggregate principal of 25% Senior Secured Convertible Promissory Notes for 6,000 shares of Series C Convertible Voting Preferred Stock.","Filed Certificate of Amendment designating 14,000 authorized shares of Series C Preferred Stock with Delaware Secretary of State.","Exchange executed under Section 3(a)(9) exemption; Series C stock issued in reliance on Section 4(a)(2) of Securities Act.","Holder released all claims related to the Exchange Notes; holding period of Preferred Stock tacks back to original note issuance."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011964","json":"https://secwatch.observer/filing/0001558370-23-011964.json","markdown":"https://secwatch.observer/filing/0001558370-23-011964.md","text":"https://secwatch.observer/filing/0001558370-23-011964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023011964/0001558370-23-011964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023011964/krbp-20230718x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:29:03.361373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a091d27f1a63332cd2df37d751e443d646c2ad7c","claim":"Kiromic Biopharma, Inc.: Filed Certificate of Amendment to the Certificate of Designation of Series C Convertible Voting Preferred Stock to designate 14,000 shares as Series C Convertible Voting Preferred Stock (effective 2023-07-18).","evidence_excerpt":"On July 18, 2023, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Voting Preferred Stock with the Delaware Secretary of State designating 14,000 shares of its authorized and unissued preferred stock as Series C Convertible Voting Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023011964/0001558370-23-011964-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-07-18"}],"fact_type":"governance_change"},{"claim_id":"c820eeae08e42caa36378efe815ed9712db211f5","claim":"Kiromic Biopharma, Inc. entered into Exchange Agreement with the holder of promissory notes valued at aggregate principal amount of $6 million (effective 2023-07-18).","evidence_excerpt":"On July 18, 2023, Kiromic BioPharma, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with the holder of promissory notes of the Company (the “Holder”) pursuant to which the Holder agreed to exchange aggregate principal amount of $6 million of the Company’s 25% Senior Secured Convertible Promissory Notes (the “Exchange Notes”) for 6,000 shares of Series C Convertible Voting Preferred Stock (the “Series C Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023011964/0001558370-23-011964-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"the holder of promissory notes"},{"label":"Value","value":"aggregate principal amount of $6 million"},{"label":"Effective","value":"2023-07-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}